All In Biotech

Drug Trial Radar · NCT07288177

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jan 30, 2026

Primary completion

Nov 22, 2027

Study completion Nov 22, 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Rina-SDrug

    Intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by InvestigatorTime frame: Approximately 3 years

Locations

102 sites in 14 countries. Site status is shown where the registry gives one.

  • Compassionate Cancer Care Center

    Fountain Valley, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Kaiser Permanente San Diego Mission Road

    San Diego, California · Recruiting

  • Providence Medical Foundation (St. Joseph Heritage Healthcare)

    Santa Rosa, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Miami Hospital

    Miami, Florida · Recruiting

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • St. Vincent Frontier Cancer Center

    Billings, Montana · Recruiting

  • Nebraska Hematology-Oncology

    Lincoln, Nebraska · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • ONE Onc: New York Oncology Hematology

    Albany, New York · Recruiting

  • Montefiore Medical Park

    The Bronx, New York · Recruiting

  • UNC Health - University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Williamette Valley Cancer Institute and Research Center

    Eugene, Oregon · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Providence Oncology & Hematology Care Clinic - Westside

    West Haven-Sylvan, Oregon · Recruiting

  • Tennessee Oncology - Nashville St. Thomas Midtown Clinic

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology Nashville - SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • St Andrews Medical Centre

    Adelaide, Australia · Recruiting

  • Blacktown Hospital

    Blacktown, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Recruiting

  • St Vincent's Hospital - Melbourne

    Fitzroy, Australia · Recruiting

  • Icon Cancer Centre Hobart

    Hobart, Australia · Recruiting

  • Icon Cancer Care - Townsville

    Hyde Park, Australia · Recruiting

  • Icon Cancer Centre Townsville ICON Cancer Care - Townsville

    Hyde Park, Australia · Recruiting

  • St George Hospital

    Kogarah, Australia · Recruiting

  • St John of God Murdoch Hospital

    Murdoch, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Australia · Recruiting

  • GenesisCare North Shore

    Saint Leonards, Australia · Recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, Belgium · Recruiting

  • Chu Helora Hospital La Louvière Site Jolimont

    La Louvière, Belgium · Recruiting

  • UZ Leuven - Gasthuisberg Campus

    Leuven, Belgium · Recruiting

  • AZ Delta (Campus Wilgenstraat)

    Roeselare, Belgium · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Beijing Chest Tumor Hospital

    Beijing, China · Recruiting

  • Jilin Provincial Cancer Hospital

    Changchun, China · Recruiting

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.